Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness | Zendy

Min Cheng | Zendy; Youhui Si | Zendy; Yang Yang | Zendy; Xuan Liu | Zendy; Qiyong Gong | Zendy; Jian Zhao | Zendy; Yamei Niu | Zendy; Xiang Li | Zendy; Qi Jin | Zendy; Wei Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness

Author(s) -

Min Cheng,

Youhui Si,

Yang Yang,

Xuan Liu,

Qiyong Gong,

Jian Zhao,

Yamei Niu,

Xiang Li,

Qi Jin,

Wei Yang

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks015

Subject(s) - hepatitis c virus , ribavirin , biology , interferon , recombinant dna , receptor , virology , pharmacology , immunology , virus , biochemistry , gene

Interleukin 28B (IL28B) genetic variation has been recently reported as a potent predictor of hepatitis C virus (HCV) response to interferon (IFN) therapy. The aim of this study was to produce recombinant human IL28B (rhIL28B) in yeast and explore the action mechanisms of rhIL28B as a novel anti-HCV agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research